Suzuken saw the highest growth of 0.99% in patent filings and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Suzuken‘s patent filings and grants. Buy the databook here.
Suzuken has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 100% of grants. The World Intellectual Property Organization(WIPO), and European Patent Office(EPO) patent Office are among the top ten patent offices where Suzuken is filings its patents. Among the top granted patent authorities, Suzuken has 100% of its grants in European Patent Office(EPO).
Roche and Sanofi could be the strongest competitors for Suzuken
Patents related to rare diseases lead Suzuken's portfolio
Suzuken has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Hypotension related patents lead Suzuken portfolio
Suzuken has highest number of patents in hypotension.
For comprehensive analysis of Suzuken's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.